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Abstract: Hypoxia is a feature of neurodegenerative diseases, and can both directly and indirectly
impact on neuronal function through modulation of glial function. Astrocytes play a key role in
regulating homeostasis within the central nervous system, and mediate hypoxia-induced changes in
response to reduced oxygen availability. The current study performed a detailed characterization
of hypoxia-induced changes in the transcriptomic profile of astrocytes in vitro. Human astrocytes
were cultured under normoxic (5% CO2, 95% air) or hypoxic conditions (1% O2, 5% CO2, 94% N2)
for 24 h, and the gene expression profile assessed by microarray analysis. In response to hypoxia
4904 genes were significantly differentially expressed (1306 upregulated and 3598 downregulated,
FC ≥ 2 and p ≤ 0.05). Analysis of the significant differentially expressed transcripts identified an
increase in immune response pathways, and dysregulation of signalling pathways, including HIF-1
(p = 0.002), and metabolism, including glycolysis (p = 0.006). To assess whether the hypoxia-induced
metabolic gene changes observed affected metabolism at a functional level, both the glycolytic and
mitochondrial flux were measured using an XF bioanalyser. In support of the transcriptomic
data, under physiological conditions hypoxia significantly reduced mitochondrial respiratory
flux (p = 0.0001) but increased basal glycolytic flux (p = 0.0313). However, when metabolically
stressed, hypoxia reduced mitochondrial spare respiratory capacity (p = 0.0485) and both glycolytic
capacity (p = 0.0001) and glycolytic reserve (p < 0.0001). In summary, the current findings detail
hypoxia-induced changes in the astrocyte transcriptome in vitro, identifying potential targets for
modifying the astrocyte response to reduced oxygen availability in pathological conditions associated
with ischaemia/hypoxia, including manipulation of mitochondrial function, metabolism, and the
immune response.
Keywords: astrocyte; hypoxia; immune response; metabolism; mitochondrial dysfunction;
transcriptome
1. Introduction
Sufficient oxygenation of the central nervous system (CNS) is essential to maintain cellular
homeostasis and metabolism. However, if the blood supply to the CNS is reduced, levels of available
oxygen decrease, resulting in a hypoxic environment. Hypoxia is also implicated in neurodegenerative
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diseases and their animal models, including Alzheimer’s disease (AD) [1–3], amyotrophic lateral
sclerosis (ALS) [4–6], and Parkinson’s disease (PD) [7,8]. Although the response to hypoxia is initially
neuroprotective with mechanisms in place to enable cells to adapt to intermittent low levels of oxygen,
extended periods of hypoxia can trigger detrimental events including neuroinflammation and oxidative
stress resulting in neuronal dysfunction and ultimately neurodegeneration [9,10].
While hypoxia has a direct impact on neuronal function, reduced oxygen levels also indirectly
impact neurones through modulation of glial function. Astrocytes play a key role in regulating
homeostasis within the CNS, including providing neuronal support, maintaining the extracellular
environment and regulating blood flow to the brain [11], and mediate hypoxia-induced changes in
blood–brain barrier permeability, neuroinflammation and neuroprotection against ischaemic injury [12].
Reduced oxygen levels increase expression of the cytokine secretome of rat astrocytes in vitro [13],
regulate innate immune responses and reactive oxygen production [14], and induce mitochondrial
dysfunction [15]. This suggests that hypoxia plays a role in modulating astrocyte function and
contributes to neurodegenerative pathology.
The transcription factor hypoxia inducible factor-1 (HIF-1) comprises a heterodimer consisting of a
constitutively expressedβ subunit and an oxygen-regulatedα subunit, and responds to reduced oxygen
availability by coordinating gene expression to adapt to the hypoxic environment. Under normoxic
conditions, HIF-1α is rapidly degraded; however, under hypoxic conditions expression of HIF-1α is
stabilised and its nuclear translocation enables it to form a heterodimer with HIF-1β. This then binds
to hypoxia responsive elements (HREs) to regulate the transcription of a variety of genes, including
those involved in physiological and pathophysiological processes such as angiogenesis, remodelling of
the extracellular matrix, cytokine production, apoptosis, and mitochondrial respiration [16,17].
Large scale transcriptomic analysis enables the genetic profile of cells/tissue to be characterized
in detail. While some studies have investigated the astrocyte response to hypoxia using a
hypothesis-driven approach studying specific candidates of interest, to date few studies have
investigated the transcriptomic profile of astrocytes in response to hypoxia in vitro. The expression
profile of rat astrocytes in response to hypoxia identified significantly differentially expressed genes
associated with energy metabolism, survival and lipoprotein binding [18], and the immune response [19],
while transcriptomic analysis of primary human astrocytes cultured under hypoxic conditions for
6 h [20] or 24 h [21] primarily identified the significant induction of genes including cell signalling and
glycolytic enzymes, respectively.
Gene expression profiling of human astrocytes in response to hypoxia may elucidate
pathological processes that can be manipulated through therapeutic intervention to ultimately prevent
neurodegeneration. Therefore, the current study performed a detailed characterization of the astrocyte
gene expression profile in response to hypoxia in vitro, extending the findings of previous reports and
identifying novel candidate gene expression changes.
2. Results
2.1. Hypoxia Significantly Alters the Astrocyte Transcriptome
Nuclear translocation of the transcription factor HIF-1α was observed in astrocytes in response
to hypoxia for 24 h (Figure 1A–F). All extracted RNA profiles from human primary astrocytes
showed distinct 18 s and 28 s ribosomal peaks by picochip analysis and had RNA Integrity Numbers
(RIN) greater than 8.5. Hypoxia-induced changes in the transcriptomic profile of human astrocytes
were generated using Human Genome U133 Plus 2.0 Arrays, which comprise 1.3 × 106 unique
oligonucleotide sequences, including >47,000 transcripts and variants of 33,000 genes. Between
46% and 60% of the probe set sequences were present across all samples (mean [range]: normoxic
59.5% [59.2–59.8%]; hypoxic 50.5% [46.3–53.2%]). No sample outliers were identified by visual
inspection of hierarchical clustering and principal component analysis, which also showed clear
separation of hypoxic and non-hypoxic samples (Figure 1G). In response to hypoxia 4904 genes
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were significantly differentially expressed (1306 upregulated (Supplementary Table S1) and 3598
downregulated (Supplementary Table S2), FC ≥ 2 and p ≤ 0.05). The expression dataset is freely
available at Gene Expression Omnibus, accession number GSE145935. To confirm a robust response to
hypoxia was induced, the dataset was interrogated to identify a comprehensive panel of published
hypoxia-inducible genes [22–24], as shown in Table 1.
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Figure 1. Hypoxia induced changes in the astrocyte gene expression profile. (A–C) Under normoxic
conditions, low levels of hypoxia inducible factor-1α (HIF-1α) are present in the cytoplasm of astrocytes;
(D–F) In response to 24 h hypoxia, HIF-1α translocates to the nucleus of astrocytes; (G) Principal
component analysis (PCA) of the transcriptomic profile of human astrocytes in response to hypoxia
demonstrates clear separation between normoxia (blue) and hypoxia (red) gene expression profiles.
Scale bar represents 100 µm (A–F).
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Table 1. Expression of hypoxia-induced transcripts
Transcript
Gene
Symbol
Gene Name FC p-Value
202912_at ADM adrenomedullin 3.4 0.011
217254_s_at EPO erythropoietin 1.9 0.039
209328_x_at HIGD2A HIG1 hypoxia inducible domain family, member 2A 1.3 0.042
209329_x_at HIGD2A HIG1 hypoxia inducible domain family, member 2A 1.6 0.040
218507_at HILPDA hypoxia inducible lipid droplet-associated 6.1 0.018
1554452_a_at HILPDA hypoxia inducible lipid droplet-associated 4.4 0.018
207092_at LEP leptin 1.6 0.030
229093_at NOS3 nitric oxide synthase 3 (endothelial cell) 6.4 0.028
205581_s_at NOS3 nitric oxide synthase 3 (endothelial cell) 1.8 0.035
217112_at PDGFB platelet-derived growth factor beta 2.3 0.048
216061_x_at PDGFB platelet-derived growth factor beta 1.8 0.028
203400_s_at TF transferrin 1.8 0.031
212171_x_at VEGFA vascular endothelial growth factor A 4.2 0.020
211527_x_at VEGFA vascular endothelial growth factor A 2.7 0.054
210513_s_at VEGFA vascular endothelial growth factor A 2.7 0.030
203683_s_at VEGFB vascular endothelial growth factor B 2.0 0.052
209946_at VEGFC vascular endothelial growth factor C 1.3 0.051
The data was initially analysed using the Database for Annotation Visualisation and Integrated
Discovery (DAVID) to identify Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and
functional groups of differentially expressed transcripts. Analysis of all significantly upregulated
genes identified signalling pathways including HIF-1 (p = 0.002) and PI3K-Akt (p = 0.005), metabolism
(glycolysis p = 0.006; fructose and mannose metabolism p = 0.04), insulin resistance (p = 0.01), and an
increased immune response (Staphylococcus aureus infection p = 0.007; HTLV-I infection p = 0.02;
Intestinal immune network for IgA production p = 0.05) (Table 2).
Table 2. Kyoto encyclopedia of genes and genomes (KEGG) pathway analysis of all significantly
upregulated genes in response to hypoxia in human astrocytes
KEGG Pathway p-Value
Hypoxia inducible factor-1 (HIF-1) signalling pathway 0.002
Phosphatidylinositol 3-kinase and protein kinase B (PI3K-Akt) signalling pathway 0.005
Renal cell carcinoma 0.006
Glycolysis/Gluconeogenesis 0.006
Staphylococcus aureus infection 0.007
Oxytocin signalling pathway 0.010
Pathways in cancer 0.013
Insulin resistance 0.014
Human T- cell leukemia virus, type 1 (HTLV-I) infection 0.019
Biosynthesis of amino acids 0.030
adenosine monophosphate-activated protein kinase (AMPK) signalling pathway 0.032
Cell adhesion molecules (CAMs) 0.035
Circadian rhythm 0.038
Fructose and mannose metabolism 0.043
Intestinal immune network for IgA production 0.045
Graft-versus-host disease 0.047
Analysis of all significantly downregulated genes identified dysregulation of pathways including
metabolism (purine metabolism p = 0.02; pyrimidine metabolism p = 0.03, tricarboxylic acid cycle
(TCA) p = 0.02), ubiquitin-mediated proteolysis (p < 0.001), and cell signalling (Wnt signalling p = 0.002;
p53 signalling p = 0.02) (Table 3). Subsequent detailed interrogation of the data focused on hypoxic
modulation of metabolism and the immune response.
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Table 3. KEGG pathway analysis of all significantly downregulated genes in response to hypoxia in
human astrocytes
KEGG Pathway p-Value
Cell cycle 6.1 × 10−9
RNA transport 1.9 × 10−7
Ubiquitin mediated proteolysis 4.5 × 10−7
Oocyte meiosis 1.9 × 10−5
Protein processing in endoplasmic reticulum 5.6 × 10−5
RNA degradation 1.6 × 10−4
Spliceosome 3.6 × 10−4
Wnt signalling 0.002
Endocytosis 0.006
Pyramidine metabolism 0.008
Progesterone-mediated oocyte maturation 0.012
Peroxisome 0.015
Tricarboxylic acid cycle (TCA cycle) 0.016
p53 signalling 0.016
DNA replication 0.019
Pathways in cancer 0.02
Purine metabolism 0.02
Valine, leucine and isoleucine degradation 0.02
RNA polymerase 0.02
Fatty acid metabolism 0.03
Protein export 0.03
Chronic myeloid leukemia 0.03
mRNA surveillance pathway 0.04
HTLV-I infection 0.04
2.2. Hypoxia Modulates the Metabolic Profile of Astrocytes
Insulin and insulin-like growth factor (IGF) primarily signal through phosphatidylinositol 3-kinase
and protein kinase B (PI3K/Akt) and mitogen-activated protein kinase (MAPK) pathways to regulate
cell growth, survival and metabolism [25]. Genes encoding insulin receptors (IR) and IGF receptors
(IGFR), as well as their receptor substrates (IRS), were significantly differentially expressed in human
astrocytes in response to hypoxia. Analysis of hypoxia-induced changes in the astrocyte transcriptome
also identified the significant dysregulation of mitochondrial-associated genes and genes associated
with metabolism (Figure 2). Transcripts associated with mitochondrial function were primarily
significantly downregulated, including: nicotinamide adenine dinucleotide plus hydrogen (NADH)
dehydrogenase subunit 3 (complex I) (ND3 probe set id: 1553588_at, FC = −2.5, p = 0.003) and
NADH dehydrogenase (ubiquinone) complex I assembly factor 4 (NDUFAF4.1 probe set id: 219006_at,
FC = −2.5, p < 0.001; probe set id: 227559_at, FC = −2.5, p = 0.004) which are involved in electron
transport chain complex 1 assembly and function; the TCA cycle associated synthetase succinate-CoA
ligase GDP-forming beta subunit (SUCLG2 probeset id: 214835_s_at, FC = −2.9, p = 0.014; probeset id:
215772_x_at, FC = −3.0, p = 0.014; probeset id: 212459_x_at, FC = −3.6, p = 0.007); and the adenosine
triphosphate (ATP) synthase subunit ATP synthase, H+ transporting, mitochondrial Fo complex
subunit C3 (subunit 9) (ATP5G3 probeset id: 207507_s_at, FC = −2.0, p = 0.025). Mitochondria and the
endoplasmic reticulum (ER) interact with each other and play a key role in a number of critical cellular
functions, including mitochondrial dynamics and bioenergetics [26]. Transcripts encoding structural
components of ER-mitochondria contact sites were dysregulated in response to hypoxia, including
mitofusin 1 (MFN1 probeset id: 207098_s_at, FC = −2.1, p = 0.025; probeset id: 217043_s_at, FC = −1.8,
p = 0.048)
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Figure 2. Heat map of mitochondrial and metabolic gene expression changes in human astrocytes in
response to hypoxia. Red: downregulated transcripts; green: upregulated transcripts.
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Conversely, genes associated with glycolytic function were significantly upregulated, including:
phosphoglycerate kinase 1 (PGK1 probeset id: 200737_at, FC = 2.3, p < 0.001), pyruvate kinase
(PKM probeset id: 213700_s_at, FC = 2.8, p = 0.008), and pyruvate dehydrogenase kinase, isozyme
3 (PDK3 probeset id: 228959_at, FC = 4.2, p < 0.001; probeset id: 206348_s_at, FC = 3.2, p < 0.001;
probeset id: 230085_at, FC = 2.7, p < 0.001), indicating a switch to a more anaerobic metabolic profile to
meet bioenergetic demands under hypoxia.
2.3. Hypoxia Modulates the Astrocyte Immune Response
Further interrogation of the datasets reducing the stringency to FC > 1.2 and focusing on
the immune response identified dysregulation in the expression of cytokines and their receptors,
predominantly upregulation of the interleukin (IL) family of cytokines (Figure 3), including IL34
(probeset id: 237046_x_at, FC = 2.1, p = 0.001), and chemoattractant cytokines (Figure 4), including
several highly upregulated transcripts for chemokine receptor 4 (CXCR4 probeset id: 217028_at,
FC = 4.2, p < 0.001; probeset id: 209201_x_at, FC = 4.0, p < 0.001; probeset id: 211919_s_at, FC = 3.6,
p = 0.003).
Figure 3. Heat map of interleukin gene expression changes in human astrocytes in response to hypoxia.
Red: downregulated transcripts; green: upregulated transcripts.
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Figure 4. Heat map of chemokine gene expression changes in human astrocytes in response to hypoxia.
Red: downregulated transcripts; green: upregulated transcripts.
Matrix metalloproteinases (MMP) are involved in remodeling of the extracellular matrix and
are upregulated as part of the neuroinflammatory response [27]. Hypoxia significantly altered the
transcription of several members of these proteases (Figure 5), including MMP10 (probeset id: 205680_at,
FC = 2.0, p = 0.004), as well as tissue inhibitor of metalloproteinase (TIMP) and a disintegrin and
metalloproteinase (ADAM) expression.
2.4. Validation of Candidate Gene Expression Changes
The altered expression of candidate genes was validated by qPCR on RNA extracted from
astrocytes in response to hypoxia, compared to normoxia, in additional independent experiments.
qPCR confirmed a significant downregulation of NDUFAF4 (Figure 6A, p = 0.001; microarray probe set
id: 219006_at, FC = −2.5, p < 0.001), MFN1 (Figure 6B, p = 0.007; microarray probeset id: 207098_s_at,
FC = −2.1, p = 0.025), SUCLG2 (Figure 6C, p = 0.02; microarray probeset id: 212459_x_at, FC = −3.6,
p = 0.007), dihydrolipoamide S-acetyltransferase (DLAT Figure 6D, p = 0.007; microarray 211150_s_at,
FC = −2.9, p < 0.001) in response to hypoxia. While the changes were non-significant, the directional
changes observed confirmed the increased expression of major histocompatibility complex, class II,
DPβ1 (HLA-DPB1 Figure 6E, p = 0.11; microarray probe set id 215193_x_at, FC = 2.6, p = 0.029),
and metallothionein 1X (MT1X Figure 6C, p = 0.08; microarray probe set id 208581_x_at, FC = 2.1,
p = 0.041) in response to hypoxia.
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Figure 5. Heat map of matrix metalloproteinase (MMP) gene expression changes in human astrocytes
in response to hypoxia. Red: downregulated transcripts; green: upregulated transcripts.
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Figure 6. qPCR validation of hypoxia induced gene expression changes in human astrocytes. qPCR
confirmed a significant downregulation of (A) NDUFAF4 (p = 0.001), (B) MFN1 (p = 0.007), (C) SUCLG2
(p = 0.02), (D) DLAT (p = 0.007); and a non-significant upregulation of (E) HLA-DPB1 (p = 0.11) and
(F) MT1X (p = 0.08) in response to hypoxia. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.
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2.5. Functional Validation of Hypoxia-Induced Changes in Astrocyte Metabolism
To assess whether the hypoxia induced metabolic gene changes observed affected metabolism
at a functional level, astrocytes were incubated under hypoxic conditions and both glycolytic and
mitochondrial flux were measured. To assess the response to stress under hypoxia, mitochondrial and
glycolytic flux were assessed under physiological conditions and under stress. Injection of oligomycin
and carbonyl cyanide p-trifluoromethoxy phenylhydrazone (FCCP) onto human astrocytes to inhibit
the mitochondrial ATP synthase and uncouple the electron transport chain (ETC) from ATP production
respectively impacted both the metabolic mitochondrial and glycolytic stress response under hypoxic
conditions (Figure 7).
 
Figure 7. Representative bioenergetic profile of astrocyte mitochondrial oxygen consumption and
glycolytic flux during hypoxia. (Upper panel) Representative astrocyte mitochondrial oxygen
consumption bioenergetic profile, showing the response of astrocyte oxygen consumption to
injection of glucose, oligomycin, carbonyl cyanide p-trifluoromethoxy phenylhydrazone (FCCP),
and rotenone/antimycin A. Blue line = normoxia, red line = hypoxia; (Lower panel) Representative
astrocyte glycolytic flux bioenergetic profile showing the response of astrocyte glycolytic flux to injection
of glucose, oligomycin, FCCP and rotenone/ antimycin A. Blue line = normoxia, red line = hypoxia.
OCR = oxygen consumption rate, ECAR = extracellular acidification rate.
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Astrocytes were initially starved of glucose to measure non glycolytic extracellular acidification
rate (ECAR, predominantly a measure of bicarbonated CO2 produced by the TCA cycle) and therefore
calculate glycolytic specific ECAR. Oxygen consumption rate (OCR) under starvation conditions
was significantly lower in the hypoxia treated astrocytes (82.6% reduction, p = 0.0004), as shown in
Figure 8A (normoxia pre-glucose versus hypoxia pre-glucose). After injection of glucose a similar
significant reduction was observed (72%, p = 0.001), as shown in Figure 8A (normoxia post-glucose
versus hypoxia post-glucose). Mitochondrial respiratory (MR) flux was significantly lower in hypoxic
astrocytes (80.7% reduction, p = 0.001) as shown in Figure 8B (normoxia MR versus hypoxia MR),
and as expected, was coupled to respiration ATP-linked flux (CR), proton leak linked flux (PL),
and mitochondrial spare respiratory capacity (SRC) linked flux (Figure 8B). As CR, PL, and SRC
flux levels are intrinsically linked to the overall level of MR flux, we analysed CR, PL, and SRC as a
percentage of MR, and detected a significant reduction in the percentage of CR in hypoxic astrocytes
(84.3 to 66.7% p < 0.0011) and an increase in the percentage of PR (15.7 to 28.2%, p = 0.0031) (Figure 8C).
Therefore, although both CR and PL flux rates were reduced in astrocytes under hypoxia the remaining
MR was less coupled than in normoxic astrocytes. Similarly, hypoxia significantly reduced SRC as a
percentage of MR (135.5 to 92.2% p = 0.0485), indicating a reduced mitochondrial capacity in hypoxia
under stress (Figure 8C). When we assessed glycolytic ECAR flux, non-glycolytic flux (NG-ECAR)
was reduced in hypoxia treated astrocytes but just failed to reach significance (p = 0.0502, unpaired
t-test) (Figure 8D). Total ECAR however, was unaltered due to a 38% increase in glycolytic specific
ECAR, which failed to reach significance when analysing raw data, but reached significance when
assessing percentage increase compared to normoxia (p = 0.0313) (Figure 8D,E). Interestingly, glycolytic
capacity and glycolytic reserve were both significantly reduced in hypoxic astrocytes (52%, p = 0.001
and 90.7% p < 0.0001, respectively) (Figure 8D). As the XF bioanalyser measures mitochondrial and
glycolytic flux simultaneously, the metabolic equilibrium (the balance between aerobic and non-aerobic
metabolism) can be assessed by calculating the OCR/ECAR ratio [28]. The higher the ratio, the more
aerobic the metabolic phenotype of the cell. Under conditions of starvation (PrG, p = 0.0057), glucose
(PsG, p = 0.0022), and stress (FCCP, p = 0.0096), the OCR/ECAR ratio was significantly lower in hypoxic
astrocytes, indicating a more anaerobic metabolic state (Figure 8F).
Figure 8. Cont.
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Figure 8. Hypoxia reduces mitochondrial respiratory function and glycolytic capacity under stress.
(A) Oxygen consumption rate in astrocytes under normoxia and hypoxia; (B) The effect of hypoxia
on mitochondrial function; (C) The effect of hypoxia on mitochondrial function as a percentage of
mitochondrial respiration; (D) The effect of hypoxia on glycolytic function; (E) The effect of hypoxia on
glycolytic flux as a percentage of normoxia; (F) The effect of hypoxia on astrocyte metabolic equilibrium.
Data presented as mean with standard deviation, each shape on the graph represents one biological
replicate, which was an average of 9–10 wells of a 24-well plate. All assays were performed in triplicate
on two independent astrocyte cell lines. Prior to statistical analysis all percentage data was transformed
1=1/Y and 1=logit(Y) prior to analysis and all data underwent distribution analysis. Subsequently an
unpaired t-test or Mann–Whitney test was performed except for panel (E) where a Wilcoxon paired
rank analysis was performed. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. OCR = oxygen
consumption rate, ECAR = extracellular acidification rate, PrG = pre glucose, PsG = post glucose,
norm = normoxia, Hypox = hypoxia, MR =mitochondrial respiration, PL = proton leak, CR = coupled
respiration, SRC = spare respiratory capacity, NG = non-glycolytic, Glyco = glycolytic, Cap = capacity,
Res = reserve, Oligo = oligomycin.
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3. Discussion
Hypoxia and an impaired response to hypoxia are implicated in the pathogenesis of several
neurodegenerative diseases. Dysregulation of both HIF-1α expression and the downstream pathways
in response to hypoxia induces motor neuron degeneration in ALS [6,29,30], and stimulates the
production ofβ-amyloid peptides and the accumulation of amyloid plaques in AD [3,31]. While reduced
oxygen availability directly impairs neuronal function, it can also indirectly impact neurones through
modulation of glial function. Astrocytes play a key role in neuronal support and maintaining
homeostasis within the CNS, and react to changes in their environment including at the genomic
level [11]. In the current study we characterized hypoxia-induced changes in the transcriptomic
profile of human astrocytes in vitro, demonstrating that reduced oxygen availability causes significant
dysregulation of genes associated with processes which play a role in neurodegenerative pathologies,
including mitochondrial function, metabolism, and immune response.
The current study assessed the effect of reduced oxygen availability (1%) on the gene expression
profile of astrocytes after 24 h. This hypoxic condition was selected based on previous studies of
the cellular response to hypoxia in vitro [19], and the time point selected to ensure that the astrocyte
response to hypoxia was optimally induced [13]. Transcriptomic analyses enable the identification
of coordinated gene expression trends that are often missed in targeted approaches [32]. To our
knowledge, only four studies have previously characterized hypoxia-associated changes in the gene
expression profile of astrocytes in vitro [18–21], and only one of these studies has assessed the human
astrocyte response to reduced oxygen availability after 24 h [21]. In contrast to the study by Mense et al.
who reported 5-fold more genes were induced as suppressed (FC > 2) [21], we detected almost 3-fold
more genes were suppressed as induced in human astrocytes in response to hypoxia using the same
U133 plus 2.0 microarray platform. Consistent with the Mense study we detected dysregulation of
genes associated with carbohydrate metabolism, signaling pathways (including insulin signaling),
apoptosis, cytokines, and growth factors. However, we also identified significant dysregulation
of mitochondrial-associated genes and a much greater number of immune-associated transcripts,
although it should be noted that at the time less than half of the genes identified in the Mense study
were annotated and had known structural or functional information.
Astrocytes play a key role maintaining homeostasis within the CNS, including regulating synaptic
transmission, modulating blood flow and permeability of the blood–brain barrier, contributing to
the immune response, and maintaining energy levels [33]. The CNS has a very demanding energy
requirement, consuming approximately 20% of the oxygen that enters the body. Mitochondria are
key organelles for cell bioenergetics, with mitochondrial oxidative phosphorylation accounting for
the vast majority of ATP generation in the CNS [34]. In contrast to neurones, astrocytes produce
significantly less ATP by oxidative phosphorylation and mainly rely on ATP generated by aerobic
glycolysis [35]. In the current study we demonstrate hypoxia-induced downregulation of a number of
transcripts associated with mitochondrial function, including those involved in electron transport chain
complex 1 assembly and function and the TCA cycle, and a significant increase in genes associated
with glycolytic function indicating a switch to a more anaerobic metabolic profile to meet bioenergetic
demands under hypoxia. These findings were validated at a functional level, by measuring metabolic
flux in real time after hypoxic treatment. Hypoxia reduced coupled mitochondrial respiration in
astrocytes and increased basal glycolytic flux, altering the metabolic equilibrium in the cell to a less
aerobic phenotype. Interestingly, when the cells were stressed by addition of mitochondrial inhibitors,
both mitochondrial and glycolytic capacity were decreased in astrocytes under hypoxia. These data
suggest that although astrocytes have the intrinsic metabolic flexibility to change to a more anaerobic
phenotype under hypoxia, if they are exposed to further stress they have less aerobic and anaerobic
bioenergetic capability. These findings have potential implications for neurodegenerative disorders,
which are multifactorial in nature involving multiple pathogenic mechanisms that lead to cellular stress.
Mitochondrial dysfunction contributes to the pathogenesis of several neurodegenerative diseases [36].
Exposure of the CNS to hypoxia may leave cells such as astrocytes metabolically vulnerable with
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less capacity to respond to stress. This could potentially exacerbate any disease state, especially in
astrocytes which play an important metabolic support role for neurones and are highly susceptible
to inflammation, for example significant metabolic defects have recently been detected in astrocytes
derived from ALS patients [28,37].
A loss of mitochondrial maximal respiratory capacity after hypoxia has been reported in neonatal
rat cardiac myocyte cultures treated with glucose and palmitate [38]. Although maximal reserve
capacity was decreased the authors did not take into account the level of spare respiratory capacity as
a factor of the baseline reading of oxygen consumption as we have done in this study. As the level of
reserve capacity respiration is intrinsically linked to the level of basal respiration, analysing the data in
terms of percentage changes in capacity gives a true reflection of the capacity of the mitochondria at
any given time. The authors measured maximal glycolytic capacity which they reported to be increased
after hypoxia but again they did not measure reserve capacity and, unlike in this study, only looked at
total ECAR rather than non-glycolytic and glycolytic ECAR. A loss of mitochondrial spare respiratory
capacity after hypoxia has also been reported in CD4+ T cells, eosinophils, and neutrophils [39,40].
In these studies, glycolytic reserve capacity was not lost in CD4+ T cells; however, non-glycolytic
ECAR was not taken into account or was not reported in eosinophils and neutrophils.
An elevated glycolytic flux rate (as measured by the rate of tritium removal from
d-[5-3H (N)]-glucose) has been observed in solid tumour models exposed to chronic hypoxia [41],
whilst elevated glycolytic flux after hypoxia has been reported in blood CD34+ hematopoietic stem
cells [42]. However, neither study reported a loss of glycolytic capacity nor measured glycolytic reserve.
To the best of our knowledge, our study is the first to report a loss of mitochondrial and glycolytic
capacity in astrocytes. Future studies to detail the relationship between astrocyte metabolism and
hypoxia in neurodegenerative diseases could identify novel targets to modify astrocyte function.
Mitochondria and the endoplasmic reticulum (ER) interact with each other and play a key
role in a number of critical cellular functions, including Ca2+ homeostasis, mitochondrial dynamics,
bioenergetics, ER stress, apoptotic signalling, and inflammation [26]. Under hypoxic conditions,
mitochondria and the (ER) move closer together, enabling the exchange of lipids and ions between
these organelles [43]. Our finding that hypoxia impacts expression of a number of transcripts
encoding structural components of ER-mitochondria contact sites, including genes encoding mitofusin,
suggesting hypoxia may contribute to the structural and functional defects of the ER-mitochondria
interface observed in a range of neurodegenerative diseases, including AD, PD, and ALS [44,45].
Neuroinflammation is a pathogenic hallmark of neurodegenerative diseases, proposed to be
involved in both their initiation and progression [46]. While some components of the inflammatory
response are neuroprotective, increased levels of neuroinflammation are associated with neuronal
dysfunction in AD [47], ALS [48], and PD [49]. Evidence from in vitro and in vivo models suggests
that neuroinflammation increases the production of oxidative species, disrupts metabolic processes,
impacts neuronal function, and causes further glial activation, as reviewed [50–52]. In the current
study, we demonstrate astrocytes respond to hypoxia by significantly upregulating expression of genes
associated with immune function.
Along with microglia, astrocytes contribute to the neuroinflammatory response in
neurodegenerative diseases by releasing effector molecules, such as cytokines, that co-ordinate the
immune response within the CNS [53,54]. The current study demonstrates that hypoxia significantly
upregulates the expression of a number of cytokine genes, predominantly the interleukin family,
and chemokine transcripts, including CXCR4. Binding to CXCR4 activates several intracellular
signalling pathways associated with chemotaxis, cell survival and/or proliferation, regulating levels of
intracellular calcium and gene transcription [55]. CXCR4-dependent astrocyte-microglia signalling has
also been shown to prevent neuronal apoptosis [56].
MMPs and their physiological inhibitors TIMPs play a role in regulating the neuroinflammatory
response, disruption of the blood–brain barrier (BBB), remodeling of the extracellular matrix and
synaptic dysfunction [27]. The expression of most MMPs, including MMP-10, is induced by cytokines
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and also upregulated after cerebral ischaemia, where they have been implicated in BBB leakage and
neurodegeneration [57]. Further work is required to assess how hypoxia-induced astrocyte expression
of MMPs and TIMPs relate to neurodegenerative pathology.
The substantive expression of immune-associated transcripts suggests a mechanism whereby
astrocytes interact with and modulate their local environment in response to reduced oxygen availability.
Targeting the immune response is a potential therapeutic strategy for a range of neurodegenerative
diseases [58]. However, while epidemiological studies originally linked the use of non-steroidal
anti-inflammatory drugs with a reduced risk of cognitive decline in AD [59], it should be noted that
more recent clinical trials suggest this treatment does not slow down the progression of dementia [60].
Furthermore, while prolonged HIF-1 activation is neurotoxic, the initial response is neuroprotective,
targeting genes which improve the supply of oxygen, promote glucose metabolism [61], and prevent
apoptosis [62]. Indeed the results of recent clinical and experimental studies suggest that increasing
HIF-1 signalling may be a strategy to postpone the onset of neurodegenerative diseases or to ameliorate
their outcome [8,63,64].
While a major limitation of the current study is the assessment of hypoxia-induced changes in the
astrocyte transcriptome in vitro, it should be noted that many of the findings correlate with in vivo
studies, thereby demonstrating the translational potential of this research. For example, post-mortem
studies of AD cerebral tissue have detected reduced cytochrome oxidase activity associated with a
reduction in energy stores which may contribute to the neurodegeneration [65]. Dysregulation in the
expression of the chemokine receptor CXCR4 has been demonstrated in a number of neurodegenerative
diseases, including AD and PD, particularly in brain regions associated with pathology [66]. Also,
MMP-9 expression by reactive astrocytes has been detected in the spinal cord of a rat model of
ischaemia-reperfusion injury [67].
In summary, the current study characterises significant changes in the transcriptomic profile
of human astrocytes in response to hypoxia in vitro, identifying potential targets for modifying
the astrocyte response to reduced oxygen availability in pathological conditions associated with
ischaemia/hypoxia, including manipulation of mitochondrial function, metabolism, and the immune
response. Future studies using a similar strategy to determine the gene expression profile of
patient-derived astrocytes may elucidate disease-specific responses. Additional histopathological
studies in well characterized patient cohorts are also required to confirm in vivo the biological relevance
of the gene expression changes identified in the human astrocyte monoculture response to hypoxia.
4. Materials and Methods
4.1. Primary Human Astrocytes
Human primary astrocytes, which we have previously characterized, were obtained from ScienCell
Research Laboratories (Carlsbad, CA, USA) [68], grown in Human Astrocyte media (ScienCell Research
Laboratories) that was supplemented with 2% fetal bovine serum (FBS), 1% penicillin streptomycin,
and 1% Astrocyte Growth Supplement (ScienCell Research Laboratories).
To confirm a response to hypoxia, astrocytes were grown to 80% confluency on coverslips in
12-well plates and incubated under either normoxic (5% CO2, 95% air) or hypoxic conditions (1% O2,
5% CO2, 94% N2) for 24 h. After fixation in 4% paraformaldehyde for 20 min at 4
◦C the cells were
washed in tris buffered saline (TBS) and permeabilised in TBS-tween (0.1% TBS-T) for 15 min at room
temperature (RT). Cells were blocked in 1.5% normal goat serum (Vector Laboratories, Peterborough,
UK) for 30 min at RT and incubated with rabbit anti-human HIF-1α (1:500 in blocking solution)
(Sigma, Gillingham, UK) overnight at 4 ◦C. After washing in TBS the cells were incubated with 1%
biotinylated goat anti-rabbit antibody (Vector Laboratories, Peterborough, UK) for 60 min at RT. Cells
were washed in TBS and incubated with streptavidin Alexa Fluor-488 (1:500) (AbCam, Cambridge,
UK) for 60 min at RT. Cells were washed in TBS, mounted in Vectastain mounting media with
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4′,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Peterborough, UK) and viewed using a
Nikon microscope (Nikon, Kingston Upon Thames, UK).
To characterize the effect of hypoxia on the astrocyte transcriptome, astrocytes were cultured
under normoxic or hypoxic conditions for 24 h. Astrocytes were lysed in 110 µL (1 mL/10 cm2)
Trizol (Life Technologies, Warrington, UK), and the RNA isolated using the Direct-Zol RNA Miniprep
Kit with Zymo-Spin™ IIC Columns (Zymo, Irvine, CA, USA). The quantity and quality of the
extracted RNA from biological repeats was assessed using the NanoDrop ND-1000 and Agilent 2100
Bioanalyser, respectively. Samples with an RNA integrity number (RIN) ≥ 8.5 were taken forward for
transcriptomic analysis.
4.2. Microarray Analysis of Hypoxia-Induced Gene Expression Changes
Double-stranded cDNA was generated from total extracted RNA using an oligo-d(T) primer with
a T7 polymerase binding site. Following this, copy RNA (cRNA) was generated to form an RNA
template which was used for a second round of amplification to synthesise double-stranded cDNA.
Biotin-labelled cRNA was generated using the Affymetrix Gene Chip in vitro transcription labelling kit
(Affymetrix, Santa Clara, CA, USA), and the quality and quantity assessed (Agilent Bioanalyser 2100,
Agilent, Cheadle, UK). The biotin-labelled cRNA (15µg) was fragmented and hybridised to Human
Genome U133 plus 2.0 Arrays for 16 h at 45 ◦C. Following hybridisation the arrays were washed and
stained using the Fluidics Station 400 and the Gene Chip Operating System (GCOS). The microarrays
were analysed using the GC3000 7G scanner and quality controls assessed using Expression Console
software (Affymetrix) and Qlucore Omics Explorer (Qlucore, Lund, Sweden). The transcriptomic data
was normalised using the robust multi-array average (RMA). A principal component analysis (PCA)
analysis was used to identify sample outliers. Significant differentially expressed genes (fold change
(FC) ≥ 2, p ≤ 0.05) were analysed using Qlucore Omics Explorer, and differentially expressed genes
visualised using Heatmapper [69]. Functional grouping and pathway analysis of the significantly
differentially expressed genes was performed using the DAVID. The dataset generated by this study is
freely available at Gene Expression Omnibus, accession number GSE145935.
4.3. Validation of Microarray Data: Quantitative Real-Time Polymerase Chain Reaction (qPCR)
RNA was extracted astrocytes cultured under normoxic or hypoxic conditions for 24 h. An IDT
PrimeTime qPCR assay (Integrated DNA Technologies, Leuven, Belgium) was performed on a total
volume of 10 µL, containing 50 ng cDNA, 500 nM primers, 250 nM probe, and Brilliant qPCR mix
(Agilent, Cheadle, UK). Details of primer sequences are shown in Table 4. The samples were denaturated
at 95 ◦C for 3 min and then amplified (40 cycles at 95 ◦C for 10 s and 60 ◦C for 30 s) using a CFX384
TouchTM RT PCR detection system (Bio-Rad, Watford, UK). The target genes were normalised to a
housekeeping gene (β-actin or GAPDH) using the ∆∆Ct calculation (ABI) [70]. Statistical analyses
were performed using IBM SPSS Statistics version 23 and GraphPad Prism version 7, and the qPCR
data analysed by Student’s paired t-test.
Table 4. qPCR primer-probe set sequences
Gene Sequence
DLAT
Probe 56-FAM/CGCTGTGCA/ZEN/ATAACCCGACGAATG/3IABkFQ
Primer 1 CCAGTTCCTACAGGTGTCTTC
Primer 2 TGAGGTATGGTTTGCTTTGATTG
HLADPB1
Probe 56-FAM/CCCACTCCA/ZEN/CAGATGATGAGCCC/3IABkFQ
Primer 1 GCTCCTCCTGTGCATGAAG
Primer 2 CAAGTGGAGCACACCAG
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Table 4. Cont.
Gene Sequence
MFN1
Probe 56-FAM/AGCTTCTAC/ZEN/TCCCACTGCTCCTACC/3IABkFQ
Primer 1 GAAATGCTCAAAGGGTGCTC
Primer 2 GTGATGCATTATCTGGCGTTG
MT1X
Probe 56-FAM/AGCTCGCCA/ZEN/TGGATCCCAACT/3IABkFQ
Primer 1 GCAACCTGTCCCGACTCTA
Primer 2 AGCTTTTCTTGCAGGAGGTG
NDUFAF4
Probe 56-FAM/CTGTGTCTT/ZEN/CCTTGCAGGTAAAAGCTG/3IABkFQ
Primer 1 CCAGAAGTTAAAGGAGAGATTGCT
Primer 2 GAATTCCTTCGGCTCTTGAC
SUCLG2
Probe 56-FAM/CACAGCTGA/ZEN/TCCTAAGGTTGAAGCCA/3IABkFQ
Primer 1 TTGGAGGTGGTGTAAAGGAAG
Primer 2 GGCAATGATGGCACAGTTG
ACTB
Probe 56-FAM/CTGCCTCCA/ZEN/CCCACTCCCA/3IABkFQ
Primer 1 GTCCCCCAACTTGAGATGTATG
Primer 2 AAGTCAGTGTACAGGTAAGCC
GAPDH
Probe 56-FAM/AAGGTCGGA/ZEN/GTCAACGGATTTGGTC/3IABkFQ
Primer 1 ACATCGCTCAGACACCATG
Primer 2 TGTAGTTGAGGTCAATGAAGGG
4.4. XF Bioanalyser Metabolic Flux Analysis
On day 1, astrocytes were plated at 20,000 cells per well in two 24-well assay plates (Agilent),
in 500 µL Human Astrocyte media (minus penicillin and streptomycin) and incubated at 37 ◦C under
normoxic conditions for 24 h. Culture media was low oxygen primed for 18 h at 37 ◦C (5% CO2, 1% O2,
94% N2, hypoxic conditions) in a H35 HEPA filtered and humidity controlled anaerobic chamber
(DW Scientific, Bingley, UK). On day 2, 1 astrocyte plate was transferred to the H35 chamber and
the media was changed for the low oxygen primed media under sterile conditions. The astrocytes
were incubated for 24 h under hypoxia. The corresponding control plate also went under a full media
change under normoxic conditions and was incubated for 24 h. On day 3, 2 XF24 probe plates (Agilent),
were calibrated with 1 ml calibration solution (Agilent) per well and incubated at 37 ◦C 0% CO2 under
normoxia or hypoxia for 24 h. Meanwhile XF assay media which consisted of XF base media (Agilent)
plus 1.5 mM glutamine and 1.0 mM sodium pyruvate was adjusted to pH 7.4, sterile filtered and half of
the media was low oxygen primed for 18 h under 3% O2 37
◦C 0% CO2 97% N2 hypoxic conditions, in a
i2 anaerobic chamber (DW Scientific) whilst the other half was incubated under normoxic conditions
in the absence of 5% CO2. On the day of the assay, the hypoxic plate was transferred to the i2 chamber
through a sealed transfer tunnel to maintain the hypoxic conditions and the media was changed to
675 µL of the low oxygen primed XF assay media. The cells were incubated in the i2 chamber for 1 h
prior to the assay starting. In the meantime, the hypoxic XF probe plate had 75 µL 58mM glucose,
82.5 µL 10 µM oligomycin, 91.6 µL 17.5 µM FCCP added to ports A, B, and C respectively. Finally,
10 µM rotenone and antimycin A was added in 100 µL of XF media to port D or 1 M Sodium sulphite
was added to port D to assess oxygen levels in the assay. All compounds were diluted 1 in 10 in the
assay. The probe plate was calibrated on the XF24 bioanalyser to quality control the probes before the
cell plate was added to the XF24 and the assay was started. At the end of the assay, all media was
removed from the wells and the plates were stored at −80 ◦C. The i2 was then opened to reach ambient
oxygen levels in the atmosphere and the assay was repeated under normoxic conditions. The next day,
the plates were defrosted and cell numbers were determined by addition of CyQUANT (Invitrogen,
Inchinnin, UK) to the cells following the manufacturer’s instructions. Briefly, a solution of 1×HBSS
buffer and 1 in 400 dilution cyquant dye was made up in water. 100 µL of this solution was added to
each well of the 24-well plate, incubated for 10 min in the dark and then fluorescence was read on a
Int. J. Mol. Sci. 2020, 21, 8028 18 of 22
BMG pherastar plate reader at 480 mm excitation 520 mm emission. The gain was set to 1% on a blank
well to control for cell numbers between assays.
Data analysis: The hypoxic plate was corrected for low oxygen tension using the XF hypoxia
rate calculator software (Agilent) with sodium sulphite as a reference. All data was then transferred
to Microsoft Excel and normalised to the CyQUANT data to correct for any cell number differences.
Mitochondrial respiration was calculated by subtracting oxygen consumption rate (OCR) in the
presence of rotenone/antimycin A from OCR in the presence of glucose only. Coupled respiration
was calculated by removing OCR in the presence of oligomycin away from mitochondrial respiration.
Uncoupled respiration was calculated by removing OCR in the presence of rotenone/antimycin A
from OCR in the presence of oligomycin. Spare respiratory capacity was calculated by subtracting
mitochondrial respiration away from OCR in the presence of FCCP. Non glycolytic extracellular
acidification rate was classed as ECAR in the absence of glucose. Glycolytic ECAR was calculated by
subtracting ECAR in the absence of glucose from ECAR in the presence of glucose. Glycolytic capacity
was calculated by removing ECAR in the presence of glucose from ECAR in the presence of oligomycin.
Finally, glycolytic reserve was calculated by subtracting glycolytic ECAR from ECAR in the presence
of oligomycin.
Statistical analysis: For the XF metabolic flux analysis to test the data for Gaussian distribution,
prior to statistical analysis, all data were assessed for normal distribution by the Kolmogorov–Smirnov,
D’Agostino–Pearson, and Sharpiro–Wilk normality tests. If normal, an unpaired t-test was performed;
if not normal, then a Mann–Whitney was performed. All percentage data were first transformed
Y = 1/Y, then subsequently Y = logit(Y) prior to analysis by unpaired t-test or Wilcoxon rank test
analysis. Statistical analysis was performed on GraphPad Prism software (version 6.0, San Diego,
CA, USA).
Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/21/21/8028/s1,
Table S1: Genes upregulated in human astrocytes in response to hypoxia. Table S2: Genes downregulated in
human astrocytes in response to hypoxia.
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Abbreviations
AD Alzheimer’s disease
ADAM a disintegrin and metalloproteinase
ALS amyotrophic lateral sclerosis
ATP adenosine tri-phosphate
CNS central nervous system
CR coupled to respiration ATP-linked flux
DAVID Database for Annotation Visualisation and Integrated Discovery
ECAR extracellular acidification rate
ETC electron transport chain
FC fold change
FCCP carbonyl cyanide p-trifluoromethoxy phenylhydrazone
HIF-1 hypoxia inducible factor-1
HREs hypoxia responsive elements
IGF insulin-like growth factor
IGFR insulin-like growth factor receptors
IL interleukin
IR insulin receptor
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IRS receptor substrates
KEGG Kyoto Encyclopedia of Genes and Genomes
MMP matrix metalloproteinases
MR mitochondrial respiratory flux
NGF non-glycolytic flux
OCR oxygen consumption rate
PD Parkinson’s disease
PL proton leak linked flux
PrG pre-glucose
PsG post-glucose
QPCR quantitative polymerase chain reaction
RIN RNA Integrity Number
SRC spare respiratory capacity
TCA tri-carboxylic acid cycle
TIMP tissue inhibitor of metalloproteinase
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